BioCentury | Jul 18, 2018
Distillery Techniques

Drug platforms

...Jeffrey A. Hubbell, University of Chicago, Chicago, Ill. email: jhubbell@uchicago.edu Allison Johnson University of Chicago Fibroblast growth factor (FGF) Laminin alpha 3 (LAMA3) Laminin...
BioCentury | Feb 17, 2014
Company News

Alexion, Prothelia, University of Nevada deal

Alexion gained an exclusive option to acquire rare disease company Prothelia, which is developing preclinical protein replacement therapy PRT-01 to treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A). Alexion may exercise its option upon achievement...
BioCentury | Feb 14, 2014
Company News

Alexion gains option to acquire Prothelia

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained an exclusive option to acquire rare disease company Prothelia Inc. (Milford, Mass.), which is developing preclinical protein replacement therapy PRT-01 to treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A). Prothelia...
BioCentury | Jan 28, 2013
Emerging Company Profile

MD Pharma AB: Dialing down autophagy

With no approved drugs for congenital muscular dystrophy, patients often die in their teens. MD Pharma AB is developing autophagy inhibitors that could extend and improve quality of life for a subgroup of patients. The...
BioCentury | Jan 24, 2011
Emerging Company Profile

Arrogene: Slick chemistry from slime

Most polymer-based nanoparticles in development to deliver cancer drugs are not covalently bound to the drug. These products carry risks of toxicity because the therapeutic agent could be released early if the nanoparticle degrades before...
Items per page:
1 - 5 of 5